BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24072346)

  • 1. Five-year follow-up of 11C-PIB uptake in Alzheimer's disease and MCI.
    Kemppainen NM; Scheinin NM; Koivunen J; Johansson J; Toivonen JT; Någren K; Rokka J; Karrasch M; Parkkola R; Rinne JO
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):283-9. PubMed ID: 24072346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.
    Hatashita S; Wakebe D
    J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.
    Ossenkoppele R; Tolboom N; Foster-Dingley JC; Adriaanse SF; Boellaard R; Yaqub M; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
    Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):990-1000. PubMed ID: 22441582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment.
    Brück A; Virta JR; Koivunen J; Koikkalainen J; Scheinin NM; Helenius H; Någren K; Helin S; Parkkola R; Viitanen M; Rinne JO
    Eur J Nucl Med Mol Imaging; 2013 Oct; 40(10):1567-72. PubMed ID: 23801168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of 11C-Pittsburgh compound-B positron emission tomography in addition to magnetic resonance imaging and single-photon emission computed tomography on diagnosis of mild cognitive impairment to Alzheimer's disease.
    Kitajima K; Abe K; Takeda M; Yoshikawa H; Ohigashi M; Osugi K; Koyama H; Yamakado K
    Medicine (Baltimore); 2021 Jan; 100(3):e23969. PubMed ID: 33545981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of (11)C-Pittsburgh compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment.
    Omachi Y; Ito K; Arima K; Matsuda H; Nakata Y; Sakata M; Sato N; Nakagome K; Motohashi N
    Psychiatry Clin Neurosci; 2015 Dec; 69(12):741-51. PubMed ID: 26085054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients.
    Byun BH; Kim BI; Park SY; Ko IO; Lee KC; Kim KM; Kim YK; Lee JY; Bu SH; Kim JH; Chi DY; Ha JH; Lim SM
    Medicine (Baltimore); 2017 Mar; 96(12):e6441. PubMed ID: 28328855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging of amyloid deposition in human brain using positron emission tomography and [18F]FACT: comparison with [11C]PIB.
    Ito H; Shinotoh H; Shimada H; Miyoshi M; Yanai K; Okamura N; Takano H; Takahashi H; Arakawa R; Kodaka F; Ono M; Eguchi Y; Higuchi M; Fukumura T; Suhara T
    Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):745-54. PubMed ID: 24233004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease.
    Hatashita S; Yamasaki H; Suzuki Y; Tanaka K; Wakebe D; Hayakawa H
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):290-300. PubMed ID: 24085503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease.
    Nordberg A; Carter SF; Rinne J; Drzezga A; Brooks DJ; Vandenberghe R; Perani D; Forsberg A; Långström B; Scheinin N; Karrasch M; Någren K; Grimmer T; Miederer I; Edison P; Okello A; Van Laere K; Nelissen N; Vandenbulcke M; Garibotto V; Almkvist O; Kalbe E; Hinz R; Herholz K
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):104-14. PubMed ID: 22961445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
    Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A
    J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Zhang S; Smailagic N; Hyde C; Noel-Storr AH; Takwoingi Y; McShane R; Feng J
    Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010386. PubMed ID: 25052054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.
    Okello A; Koivunen J; Edison P; Archer HA; Turkheimer FE; Någren K; Bullock R; Walker Z; Kennedy A; Fox NC; Rossor MN; Rinne JO; Brooks DJ
    Neurology; 2009 Sep; 73(10):754-60. PubMed ID: 19587325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
    Hatashita S; Yamasaki H
    PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
    Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer's disease: a longitudinal PET study.
    Ismail R; Parbo P; Madsen LS; Hansen AK; Hansen KV; Schaldemose JL; Kjeldsen PL; Stokholm MG; Gottrup H; Eskildsen SF; Brooks DJ
    J Neuroinflammation; 2020 May; 17(1):151. PubMed ID: 32375809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive decline and amyloid accumulation in patients with mild cognitive impairment.
    Koivunen J; Karrasch M; Scheinin NM; Aalto S; Vahlberg T; Någren K; Helin S; Viitanen M; Rinne JO
    Dement Geriatr Cogn Disord; 2012; 34(1):31-7. PubMed ID: 22868352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.
    Li Y; Rinne JO; Mosconi L; Pirraglia E; Rusinek H; DeSanti S; Kemppainen N; Någren K; Kim BC; Tsui W; de Leon MJ
    Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2169-81. PubMed ID: 18566819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.